Filing Details
- Accession Number:
- 0001209191-23-058576
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-12-13 21:34:24
- Reporting Period:
- 2023-12-11
- Accepted Time:
- 2023-12-13 21:34:24
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1484565 | Soleno Therapeutics Inc | SLNO | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1422484 | H James Mackaness | 203 Redwood Shores Pkwy, Ste 500 Redwood City CA 94065 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-12-11 | 15,000 | $2.60 | 44,610 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-12-11 | 6,252 | $35.49 | 38,358 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-12-11 | 12,381 | $36.16 | 25,977 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-12-11 | 13,849 | $37.06 | 12,128 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee stock option (right to buy) | Disposition | 2023-12-11 | 15,000 | $0.00 | 15,000 | $2.60 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 5,000 | 2032-07-27 | No | 4 | M | Direct |
Footnotes
- The 1-for-15 reverse stock split of the Issuer's Common Stock, effected August 26, 2022, was reflected in a Form 4 filed by the Reporting Person on October 14, 2023. The number of shares reported as beneficially owned following the reported transaction has been reduced by two shares to reflect share rounding as a result of such stock split.
- This transaction was executed in multiple trades at prices ranging from $34.83 to $35.82. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $35.83 to $36.76. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $36.84 to $37.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- The option, originally for 20,000 shares, vested as to one fourth of the shares on August 1, 2022 and each three-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date.
Billionaire Hedge Funds
